Stelara, Treatment for Moderate-to-Severe Crohn’s Disease, Approved for Use in EU

Stelara, Treatment for Moderate-to-Severe Crohn’s Disease, Approved for Use in EU
The European Commission (EC) has approved Stelara (ustekinumab) for the treatment of adults with moderate-to-severe Crohn’s disease who had no improvements with other therapies, the drug developer’s, Janssen, announced. Stelara is a monoclonal antibody antagonist of human interleukin-12 and interleukin-23, molecules that are believed to play a role in the autoimmunity that leads to disorders such

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *